Ambrx Biopharma shareholders approve acquisition by Johnson & Johnson

Ambrx Biopharma (AMAM) announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson (JNJ) at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction. More than 99% of the votes cast at the Special Meeting were voted in favor of adopting the Merger Agreement. Ambrx will disclose the final vote results, as certified by the independent inspector of elections, on a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission. Ambrx now expects to complete the transaction on or about March 7, 2024, subject to the satisfaction of customary closing conditions.